Altered gut microbiota correlate with different immune responses to HAART in HIV-infected individualsOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This case-control study asked whether gut microbiota differ between HIV patients who recover CD4 T-cells on therapy and those who do not. Researchers linked bacterial composition to markers of immune activation, inflammation, and bacterial translocation. Fecal microbiota were characterized by 16S ribosomal RNA gene V3-V4 region sequencing on the Illumina MiSeq platform. T-cell activation and senescence were measured by flow cytometry. Plasma lipopolysaccharide, soluble CD14, and twelve cytokines were quantified. Bacteria were correlated with immune measures using Spearman analysis.
Who was studied?
The study enrolled 94 adults in Hangzhou, China: 28 immunological responders, 30 immunological non-responders, and 36 healthy controls. Responders had CD4 counts of 500 cells per microliter or more, and non-responders under 200, after two years of viral suppression on antiretroviral therapy. All HIV-positive participants had undetectable viral loads and no comorbidities. People with hepatitis, opportunistic infections, recent antibiotics, or inflammatory bowel disease were excluded. Groups were matched for age, sex, and body mass index.
What were the most important findings?
Both responder and non-responder groups showed persistent gut dysbiosis versus controls, with reduced diversity that did not differ between the two patient groups. Fusobacterium, Ruminococcus gnavus, and Megamonas were enriched, while Faecalibacterium, Alistipes, Bifidobacterium, Eubacterium rectale, and Roseburia were depleted. Ruminococcaceae and Alistipes correlated positively with nadir and current CD4 counts and negatively with CD8+CD57+ T-cells. Inflammation markers and LPS rose with Ruminococcus and Fusobacterium but fell with Faecalibacterium. Escherichia-Shigella and Blautia were significantly higher in responders than non-responders.
What are the greatest implications of this study?
The findings suggest gut dysbiosis persists despite successful viral suppression and may be one factor shaping how well immune function recovers on therapy. Specific genera tracked with CD4 recovery, immune activation, and translocation. Because samples were taken only after treatment and the design is correlational, the study cannot show whether microbiota drive immune outcomes or reflect them. Diet and living conditions may have biased results. The authors point to Escherichia-Shigella and Blautia as candidate genera linked to differing treatment outcomes, warranting direct manipulation studies.